Abstract:OBJECTIVE:In recent years, the combination of cetuximab and chemoradiotherapy (CRT) has been used to treat stage III non-small cell lung cancer (NSCLC); however, limited data are available for Chinese patients. Herein, we report preliminary data from a phase I/II study testing the combination of cetuximab with inductive chemotherapy, followed by concurrent CRT (CCRT) in Chinese patients with stage III NSCLC.METHODS:Eligibility criteria were Zubrod performance status (PS) 0-1, forced expiratory volume in 1 second (FEV1) ≥1.2 L and adequate organ function. Enrolled patients received weekly cetuximab (initial dose of 400 mg/m(2) on day 1 of week 1 and a maintenance dose of 250 mg/m(2) on week 2 to the end of CCRT) with cisplatin/vinorelbine (NP) chemotherapy (every 3 weeks for 2 cycles from week 2, followed by two cycles of concomitant NP chemotherapy and intensity-modulated thoracic radiotherapy (TRT) (60-66 Gy/2 Gy). The primary endpoints were toxicity and feasibility. All patients received positron emission tomography-computerized tomography (PET-CT) scans within the 2 weeks prior to enrollment. Univariate analyses were used to assess the correlation between SUV-T, SUV-N, SUV-TOTAL, gender, age, histology, tumor-node-metastasis (TNM) stage, PS and smoking status and survival. Survival curves were generated for different populations using the Kaplan-Meier method and compared using a log-rank test.RESULTS:Seventeen patients were enrolled and 16 completed the full regime. The overall response rate (ORR) was 58.8% and 82.3% after the induction and CCRT phases, respectively. With a median follow-up duration of 27.6 months, the median survival was 27.6 months [95% confidence interval (CI): 11.3-43.9 months] with 1- and 2-year survival rates of 88.2% (95% CI, 60.6-96.9%) and 58.8% (95% CI, 60.6-77.8%), respectively. Three patients remain progression-free to date, and the median progression-free survival (PFS) was 13.5 months (95% CI, 6.8-20.2 months). No treatment-related death occurred; however, 76% of the patients experienced grade 3+ adverse events (AEs), including nausea/vomiting, intestinal obstruction, and esophagitis (<6%), while other AEs were mostly of hematological nature (71%). The cut-off values for SUV-T and SUV-TOTAL were 11 and 20, respectively. Univariate analyses revealed SUV-TOTAL (P=0.027), SUV-T (P=0.025), and PS (P=0.006) as potential survival predictors, with a hazard ratio (HR) of 3.4, 3.7, and 9.9, respectively.CONCLUSIONS:The combination of cetuximab with induction chemotherapy followed by CCRT appears feasible and promising. Local and locoregional maximal SUVs, defined by (18)F-FDG PET-CT scanning, may represent a prognostic indicator for long-term survival for these patients, which warrants further study.

Short-term Outcomes of Cetuximab Combined with Standard Chemotherapy As Non-First Line Setting for Patients with Non-Small Cell Lung Cancer: a Report of 6 Cases

Efficacy of Pemetrexed Plus Platinum Doublet Chemotherapy As First-Line Treatment for Advanced Nonsquamous Non-Small-cell-lung Cancer: a Systematic Review and Meta-Analysis.

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Patients with Kras Wild-Type Unresectable Colorectal Liver-Limited Metastases: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial (clime Study)

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Unresectable Liver Metastasis from Colorectal Cancer: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial

Cetuximab Combination with Chemotherapy in Advanced Non-Small Cell Lung Cancer

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Camrelizumab Plus Carboplatin and Pemetrexed As First-Line Therapy for Advanced Non-Squamous Non-Small-cell Lung Cancer: 5-Year Outcomes of the CameL Randomized Phase 3 Study

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Phase II Trial of a 2-H Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small-cell Lung Cancer

Use of Cetuximab After Failure of Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer

Feasibility of Cetuximab and Chemoradiotherapy Combination in Chinese Patients with Unresectable Stage III Non-Small Cell Lung Cancer: a Preliminary Report.

Combined Taxane, Platinum, and Cetuximab As a First‐line Treatment for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Study

Platinum-Based Chemotherapy Plus Cetuximab First-Line for Asian Patients with Recurrent And/Or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of an Open-Label, Single-Arm, Multicenter Trial

Retrospective Study of Cetuximab in Combination with Chemotherapy for Patients with Colorectal Cancer

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation

Cetuximab in Combination with Chemoradiation after Induction Chemotherapy of Locoregionally Advanced Nasopharyngeal Carcinoma: Preliminary Results

[Cetuximab in Combination with Chemotherapy for Patients with Gastrointestinal Cancer].

Induction Chemotherapy with Cetuximab, Vinorelbine-Cisplatin Followed by Intensity Modulated Thoracic Radiation Therapy and Concurrent Cetuximab, Vinorelbine-Cisplatin in Patients with Unresectable Stage III Non-small Cell Lung Cancer

Study of Gefitinib and Pemetrexed As First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation

Right- and Left-Sided Colorectal Cancers Respond Differently to Cetuximab

Enterprise Architecture as a Way of Synchronizing Enterprise Resource Planning Systems and Business Processes